

Welcome to the Integrated Research Application System

IRAS Project Filter

The integrated dataset required for your project will be created from the answers you give to the following questions. The system will generate only those questions and sections which (a) apply to your study type and (b) are required by the bodies reviewing your study. Please ensure you answer all the questions before proceeding with your applications.

Please complete the questions in order. If you change the response to a question, please select 'Save' and review all the questions as your change may have affected subsequent questions.

Please enter a short title for this project (maximum 70 characters)

RECOVERY trial

1. Is your project research?

☒ Yes ☐ No

2. Select one category from the list below:

- ☒ Clinical trial of an investigational medicinal product
- ☐ Clinical investigation or other study of a medical device
- ☐ Combined trial of an investigational medicinal product and an investigational medical device
- ☐ Other clinical trial to study a novel intervention or randomised clinical trial to compare interventions in clinical practice
- ☐ Basic science study involving procedures with human participants
- ☐ Study administering questionnaires/interviews for quantitative analysis, or using mixed quantitative/qualitative methodology
- ☐ Study involving qualitative methods only
- ☐ Study limited to working with human tissue samples (or other human biological samples) and data (specific project only)
- ☐ Study limited to working with data (specific project only)
- ☐ Research tissue bank
- ☐ Research database

If your work does not fit any of these categories, select the option below:

☐ Other study

2a. Is this a commercially sponsored Phase 1 or Phase 1/2a trial involving healthy volunteers?

☐ Yes ☒ No

2b. Will the study involve the use of any medical device without a CE Mark, or a CE marked device which has been modified or will be used outside its intended purposes?

☐ Yes ☒ No

2c. Please answer the following question:

Is this trial subject to advice from the Expert Advisory Group on Clinical Trials and the Commission on Human Medicine prior to authorisation from MHRA?

☐ Yes ☒ No

2d. Please answer the following question:

Is this a trial of a gene therapy medicinal product?

☐ Yes ☒ No

2e. Please answer the following question(s):

a) Does the study involve the use of any ionising radiation?

☐ Yes ☒ No

b) Will you be taking new human tissue samples (or other human biological samples)?

☐ Yes ☒ No

c) Will you be using existing human tissue samples (or other human biological samples)?

☐ Yes ☒ No

3. In which countries of the UK will the research sites be located?(Tick all that apply)

- ☒ England
- ☒ Scotland
- ☒ Wales
- ☒ Northern Ireland

3a. In which country of the UK will the lead NHS R&D office be located:

- ☒ England
- ☐ Scotland
- ☐ Wales
- ☐ Northern Ireland
- ☐ This study does not involve the NHS

4. Which applications do you require?

- ☒ IRAS Form
- ☒ Medicines and Healthcare products Regulatory Agency (MHRA) – Medicines
- ☒ Confidentiality Advisory Group (CAG)
- ☐ Her Majesty's Prison and Probation Service (HMPPS)

4a. Will you be seeking data from Hospital Episode Statistics (HES) or the Secondary Uses Service (SUS)?

☐ Yes ☒ No

5. Will any research sites in this study be NHS organisations?

☒ Yes ☐ No

5a. Are all the research costs and infrastructure costs (funding for the support and facilities needed to carry out research e.g. NHS Support costs) for this study provided by a NIHR Biomedical Research Centre, NIHR Collaboration for Leadership in Health Research and Care (CLAHRC), NIHR Patient Safety Translational Research Centre or Medtech and In Vitro Diagnostic Cooperative in all study sites?

Please see information button for further details.

☐ Yes ☒ No

Please see information button for further details.

5b. Do you wish to make an application for the study to be considered for NIHR Clinical Research Network (CRN) Support and inclusion in the NIHR Clinical Research Network Portfolio?

Please see information button for further details.

☒ Yes ☐ No

The NIHR Clinical Research Network provides researchers with the practical support they need to make clinical studies happen in the NHS e.g. by providing access to the people and facilities needed to carry out research "on the ground".

If you select yes to this question, you must complete a NIHR Clinical Research Network (CRN) Portfolio Application Form (PAF) immediately after completing this project filter question and before submitting other applications. Failing to complete the PAF ahead of other applications e.g. HRA Approval, may mean that you will be unable to access NIHR CRN Support for your study.

6. Do you plan to include any participants who are children?

☐ Yes ☒ No

7. Do you plan at any stage of the project to undertake intrusive research involving adults lacking capacity to consent for themselves?

☒ Yes ☐ No

Answer Yes if you plan to recruit living participants aged 16 or over who lack capacity, or to retain them in the study following loss of capacity. Intrusive research means any research with the living requiring consent in law. This includes use of identifiable tissue samples or personal information, except where application is being made to the Confidentiality Advisory Group to set aside the common law duty of confidentiality in England and Wales. Please consult the guidance notes for further information on the legal frameworks for research involving adults lacking capacity in the UK.

8. Do you plan to include any participants who are prisoners or young offenders in the custody of HM Prison Service or who are offenders supervised by the probation service in England or Wales?

☐ Yes ☒ No

9. Is the study or any part of it being undertaken as an educational project?

☐ Yes ☒ No

10. Will this research be financially supported by the United States Department of Health and Human Services or any of its divisions, agencies or programs?

☐ Yes ☒ No

11. Will identifiable patient data be accessed outside the care team without prior consent at any stage of the project (including identification of potential participants)?

☐ Yes ☒ No

SUBSTANTIAL AMENDMENT FORM ¹

NOTIFICATION OF A SUBSTANTIAL AMENDMENT TO A CLINICAL TRIAL ON A MEDICINAL PRODUCT FOR HUMAN USE TO THE COMPETENT AUTHORITIES AND FOR OPINION OF THE ETHICS COMMITTEES IN THE EUROPEAN UNION

For official use:

Date of receiving the request:	Grounds for non acceptance/negative opinion:
	Date:
Date of start of procedure:	Authorisation/ positive opinion:
	Date:
Competent authority registration number of the trial:	Withdrawal of amendment application:
Ethics committee registration number of the trial:	Date:

To be filled in by the applicant:

*This form is to be used both for a request to the Competent Authority for authorisation of a **substantial** amendment and to an Ethics Committee for its opinion on a **substantial** amendment. Please indicate the relevant purpose in Section A.*

A TYPE OF NOTIFICATION

A.1 Member State in which the substantial amendment is being submitted:

United Kingdom

A.2 Notification for authorisation to the competent authority:



A.3 Notification for an opinion to the ethics committee:



(¹) Cf. Section 3.7.b of the Detailed guidance on the request to the competent authorities for authorisation of a clinical trial on a medicinal product for human use, the notification of substantial amendments and the declaration of the end of the trial (OJ, C82, 30.3.2010, p.1) hereinafter referred to as 'detailed guidance CT-1'.

B TRIAL IDENTIFICATION (When the amendment concerns more than one trial, repeat this form as necessary.)

B.1 Does the substantial amendment concern several trials involving the same IMP? ² ☐ Yes ☒ No

B.2 EudraCT number: 2020-001113-21

B.3 Full title of the trial: Randomised evaluation of COVID-19 therapy

B.4 Sponsor's protocol code number: NDPHRECOVERY

B.4 Sponsor's protocol version number: 4.0

B.4 Sponsor's protocol date: 14/04/2020

(²) Cf. Section 3.7. of the detailed guidance CT-1

C IDENTIFICATION OF THE SPONSOR RESPONSIBLE FOR THE REQUEST

C.1 Sponsor

Organisation: University of Oxford
 Contact Given name: Heather
 Contact Family name: House
 Address: Clinical Trials & Research Governance
 Town/city: 1st Floor, Boundary Brook House, Churchill Drive
 Post code: OX3 7GB
 Telephone: 00000
 Fax: 00000
 E-mail: ctrg@admin.ox.ac.uk

C.2 Legal representative ³ of the sponsor in the European Union for the purpose of this trial (if different from the sponsor)

Name of organisation:
 Contact Given name:
 Contact Family name:
 Address:
 Town/city:
 Post code:
 Telephone:
 Fax:
 E-mail:

(3) As stated in Article 19 of Directive 2001/20/EC.

D APPLICANT IDENTIFICATION, (please tick the appropriate box)

D1. Request for the competent authority

- D.1.1 Sponsor ☐
 D.1.2 Legal representative of the sponsor ☐
 D.1.3 Person or organisation authorised by the sponsor to make the application. ☒
 D.1.4 Complete below:

Name of organisation University of Oxford
 Contact Given name Peter
 Contact Family name Horby
 Address New Richards Building
 Town/city Old Road Campus,
 Headington
 Post code OX3 7LG
 Telephone 01865612940
 Fax 00000

E-mail peter.horby@ndm.ox.ac.uk

D2. Request for the Ethics Committee

- D.2.1 Sponsor ☐
- D.2.2 Legal representative of the sponsor ☐
- D.2.3 Person or organisation authorised by the sponsor to make the application. ☐
- D.2.4 Investigator in charge of the application if applicable⁴:
- Co-ordinating investigator (for multicentre trial): ☒
 - Principal investigator (for single centre trial): ☐
- D.2.5 Complete below:

Name of organisation University of Oxford

Given name Peter

Family name Horby

Address New Richards Building

Town/city Old Road Campus,
Headington

Post code OX3 7LG

Telephone 01865612940

Fax 00000

E-mail peter.horby@ndm.ox.ac.uk

⁽⁴⁾ According to national legislation.**E SUBSTANTIAL AMENDMENT IDENTIFICATION****E.1 Sponsor's substantial amendment information for the clinical trial concerned:**

Code Number: SA3

Version: 1.0

Date: 2020/04/14

E.2 Type of substantial amendmentE.2.1 Amendment to information in the CT application form ☒ Yes ☐ NoE.2.2 Amendment to the protocol ☒ Yes ☐ NoE.2.3 Amendment to other documents appended to the initial application form ☒ Yes ☐ No

If yes specify:

Participant Information Sheet and Informed Consent Form

E.2.4 Amendment to other documents or information: ☐ Yes ☒ No

If yes specify:

E.2.5 This amendment concerns mainly urgent safety measures already implemented⁵: ☐ Yes ☒ NoE.2.6 This amendment is to notify a temporary halt of the trial⁶: ☐ Yes ☒ NoE.2.7 This amendment is to request the restart of the trial⁷: ☐ Yes ☒ No

⁽⁵⁾ Cf. Section 3.9. of the detailed guidance CT-1.

⁽⁶⁾ Cf. Section 3.10. of the detailed guidance CT-1

⁽⁷⁾ Cf. Section 3.10. of the detailed guidance CT-1

E.3 Reasons for the substantial amendment:

E.3.1 Changes in safety or integrity of trial subjects ☐ Yes ☒ No

E.3.2 Changes in interpretation of scientific documents/value of the trial ☐ Yes ☒ No

E.3.3 Changes in quality of IMP(s) ☐ Yes ☒ No

E.3.4 Changes in conduct or management of the trial ☐ Yes ☒ No

E.3.5 Change or addition of principal investigator(s), co-ordinating investigator ☐ Yes ☒ No

E.3.6 Change/addition of site(s) ☐ Yes ☒ No

E.3.7 Other change ☒ Yes ☐ No

E.3.7.1 If yes specify:

Addition of second randomisation for participants who deteriorate after entry into the trial.

Creation of animation of Participant Information Sheet.

E.3.8 Other case ☐ Yes ☒ No

E.3.8.1 If yes specify:

E.4 Information on temporary halt of trial:⁸

E.4.1 Date of temporary halt

E.4.2 Recruitment has been stopped ☐ Yes ☐ No

E.4.3 Treatment has been stopped ☐ Yes ☐ No

E.4.4 Number of patients still receiving treatment at time of the temporary halt in the MS concerned by the amendment

E.4.5 Briefly describe:

Justification for a temporary halt of the trial (*free text*):

The proposed management of patients receiving treatment at time of the halt (*free text*):

The consequences of the temporary halt for the evaluation of the results and for overall risk benefit assessment of the investigational medicinal product (*free text*):

⁽⁸⁾Cf. Section 3.10. of the detailed guidance CT-1

F DESCRIPTION OF EACH SUBSTANTIAL AMENDMENT⁹

Please use this section to detail each substantial amendment which is being notified. If you are notifying more than one substantial amendment, please use the "Add Amendment" button as required

Substantial amendment 1

Previous and new wording:(tracked)

Section 1.2.2 Second randomization for patients with progressive COVID-19

Severe COVID-19 is associated with release of pro-inflammatory cytokines, such as IL-1, IL-6 and TNF α , and other markers of systemic inflammation including ferritin and C-reactive protein. There is a possibility that this response may cause or exacerbate lung injury, leading to life-threatening disease.

Participants with progressive COVID-19 (as evidenced by hypoxia and an inflammatory state) may undergo an optional second randomisation between the following treatment arms:

No additional treatment: There are currently no approved immunomodulatory or other host-directed treatments to prevent the progression of COVID-19.

Tocilizumab: Tocilizumab is an interleukin-6 (IL-6) receptor antibody which blocks a component of the immune response that may drive progression to ARDS.

AND

Section 2.6: Second randomisation for patients with progressive COVID-19

Patients enrolled in the main RECOVERY trial and with clinical evidence of a hyper-inflammatory state may be considered for a second randomisation if they meet the following criteria:

1. Randomised into the main RECOVERY trial no more than 21 days ago
2. Clinical evidence of progressive COVID-19:
 1. oxygen saturation <92% on room air or requiring oxygen; and
 2. C-reactive protein \geq 75 mg/L
3. No medical history that might, in the opinion of the attending clinician, put the patient at significant risk if he/she were to participate in this aspect of the RECOVERY trial

Note: Participants may undergo this second randomisation at any point after being randomised to one of the main treatment arms, provided they meet the above criteria. For example, for some participants this may be immediate but for others it may occur a few hours or days later, if and when they deteriorate.

The following information will be recorded (on the web-based form) by the attending clinician or delegate:

- Patient details (e.g. name, NHS number, date of birth, sex)
- Clinician details (e.g. name)
- COVID-19 severity as assessed by need for supplemental oxygen or ventilation/extracorporeal membrane oxygenation
- Markers of progressive COVID-19 (oxygen saturation, C-reactive protein)
- Contraindication to the study drug treatments (in the opinion of the attending clinician)
- Name of person completing the form

The person completing the form will then be asked to confirm that they wish to randomise the patient and will then be required to enter their name and e-mail address.

Eligible participants may be randomised between the following treatment arms:

- **No additional treatment:** There are currently no approved anti-viral or host-directed treatments for COVID-19.
- **Tocilizumab** by intravenous infusion with the dose determined by body weight:

Weight*	Dose
>40 ≤65 kg	400 mg
>65 ≤90 kg	600 mg
>90 kg	800 mg

* for lower weights, dosing should be 8 mg/kg

(Note: Body weight may be estimated if it is impractical to weigh the patient.)

Tocilizumab should be given as a single intravenous infusion over 60 minutes in 100ml sodium chloride 0.9%. A second dose may be given ≥12 and <24 hours later if, in the opinion of the attending clinician, the patient's condition has not improved.

The randomisation program will allocate patients in a ratio of 1:1 between two arms.

New wording:

As above

Comments/ explanation/ reasons for substantial amendment:

In recognition that many patients hospitalised with Covid-19 deteriorate after admission and develop a clinical picture similar to cytokine release syndrome (CRS) we wish to test whether immunomodulatory therapy may improve prognosis. Tocilizumab (an anti-interleukin 6 receptor antagonist) has a license for the treatment of CRS so we wish to test this in RECOVERY.

Participants who meet criteria to indicate both physiological (reduced oxygen levels in their blood) and inflammatory (increased levels of a commonly-measured inflammation marker, CRP) deterioration will be eligible to be randomised for a second time (ie, after the main randomisation at entry to RECOVERY) between tocilizumab and control (ie, standard care alone). The outcomes will be the same (and collected at the same time) as the main randomisation.

Consent for this second randomisation will be obtained at the time of entry into the trial because if this deterioration occurs it is unlikely that participants will have capacity to give consent a second time. For participants still in hospital and already participating in RECOVERY at the time that this amendment is approved will not be asked to provide consent because it is unlikely that they have capacity and their doctors would only enter them into this second phase if they consider it to be in their best interests.

Substantial amendment 2

Previous and new wording:(tracked)

Section 2.1: For patients who lack capacity, an advanced directive or behaviour that clearly indicates that they would

not wish to participate in the trial would be considered sufficient reason to exclude them from the trial.

AND

Footnote to define "suspected SARS-CoV-2 infection": In general, SARS-CoV-2 infection should be suspected when a patient presents with (i) typical symptoms (e.g. influenza-like illness with fever and muscle pain, or respiratory illness with cough and shortness of breath); and (ii) compatible chest X-ray findings (consolidation or ground-glass shadowing); and (iii) alternative causes have been considered unlikely or excluded (e.g. heart failure, influenza). However, the diagnosis remains a clinical one based on the opinion of the managing doctor.

New wording:

As above

Comments/ explanation/ reasons for substantial amendment:

These have been added at the request of the Ethics Committee after the previous substantial amendment.

Substantial amendment 3

Previous and new wording:*(tracked)*

Section 2.7 (collection of outcome information):

- Use of any medications included in the RECOVERY trial protocol (including drugs in the same class)

New wording:

As above

Comments/ explanation/ reasons for substantial amendment:

We wish to collect simple information on the treatments actually received by participants so we can assess adherence to the randomised allocation.

Substantial amendment 4

Previous and new wording:*(tracked)*

We have commissioned an animation of the Participant Information Sheet (PIS).

New wording:

Comments/ explanation/ reasons for substantial amendment:

The storyboard for this animation is included in the attachments. It is intended to be used alongside (not instead of) the existing paper PIS, but we hope will provide an accessible introduction to the trial and assist in ensuring that consent is properly informed.

Substantial amendment 5

Previous and new wording:*(tracked)*

Administrative and typographical corrections.

New wording:

As above

Comments/ explanation/ reasons for substantial amendment:

(9) Cf. Section 3.7.c. of the detailed guidance CT-1. The sponsor may submit this documentation on a separate sheet.

G CHANGE OF CLINICAL TRIAL SITE(S)/INVESTIGATOR(S) IN THE MEMBER STATE CONCERNED BY THIS AMENDMENT

Type of change:

G.1.1 Addition of a new site

G.1.1.1 Principal investigator (provide details below)

Given name
Middle name(if
applicable)
Family name
Qualification
(MD...)
Professional
address

G.1.2 Removal of an existing site

G.1.2.1 Principal investigator (provide details below)

Given name
Middle name(if
applicable)
Family name
Qualification
(MD...)
Professional
address

G.1.3 Change of co-ordinating investigator (provide details below of the new coordinating investigator)

Given name
Middle name(if
applicable)
Family name
Qualification
(MD...)
Professional
address

G.1.3.6 Indicate the name of the previous co-ordinating investigator:

G.1.4 Change of principal investigator at an existing site (provide details below of the new principal investigator)

Given name
Middle name(if
applicable)
Family name
Qualification
(MD...)

Professional
address

G.1.4.6 Indicate the name of the previous principal investigator:

H CHANGE OF INSTRUCTIONS TO CA FOR FEEDBACK TO SPONSOR**H.1 Change of e-mail contact for feedback on application*****H.2 Change to request to receive an .xml copy of CTA data**☐ Yes ☒ No

H.2.1 Do you want a .xml file copy of the CTA form data saved on EudraCT?

☐ Yes ☐ No

H.2.1.1 If yes provide the e-mail address(es) to which it should be sent (up to 5 addresses):

H.2.2 Do you want to receive this via password protected link(s)¹⁰?☐ Yes ☐ No

If you answer no to question H.2.2 the .xml file will be transmitted by less secure e-mail link(s)

H.2.3 Do you want to stop messages to an email for which they were previously requested?☐ Yes ☐ No

H.2.3.1 If yes provide the e-mail address(es) to which feedback should no longer be sent:

(*This will only come into effect from the time at which the request is processed in EudraCT).

⁽¹⁰⁾ This requires a EudraLink account. (See eudract.emea.europa.eu for details)**I LIST OF THE DOCUMENTS APPENDED TO THE NOTIFICATION FORM (cf. Section 3.7 of detailed guidance CT-1)***Please submit only relevant documents and/or when applicable make clear references to the ones already submitted. Make clear references to any changes of separate pages and submit old and new texts. Tick the appropriate box(es).***I.1 Cover letter****I.2 Extract from the amended document in accordance with Section 3.7.c. of detailed guidance CT-1 (if not contained in Part F of this form)****I.3 Entire new version of the document¹¹****I.4 Supporting information****I.5 Revised .xml file and copy of initial application form with amended data highlighted****I.6 Comments on any novel aspect of the amendment if any :**

We have also added information on prednisolone and hydrocortisone to the IMP section of the CTA application, as requested by the MHRA in their approval letter for Substantial Amendment 2.

⁽¹¹⁾ Cf. Section 3.7.c. of the detailed guidance CT-1**J SIGNATURE OF THE APPLICANT IN THE MEMBER STATE***Please submit only relevant documents and/or when applicable make clear references to the ones already submitted.*

Make clear references to any changes of separate pages and submit old and new texts. Tick the appropriate box(es).

J.1 I hereby confirm that/ confirm on behalf of the sponsor that (delete which is not applicable)

- The above information given on this request is correct;
- The trial will be conducted according to the protocol, national regulation and the principles of good clinical practice; and
- It is reasonable for the proposed amendment to be undertaken.

J.2 APPLICANT OF THE REQUEST FOR THE COMPETENT AUTHORITY(as stated in section D.1): ☒

J.2.1 Signature ¹²:

J.2.2 Print name: Peter Horby

J.2.3 Date: 2020/04/14

J.3 APPLICANT OF THE REQUEST FOR THE ETHICS COMMITTEE (as stated in section D.2): ☒

J.3.1 Signature ¹³:

J.3.2 Print name: Peter Horby

J.3.3 Date: 2020/04/14

(12) On an application to the Competent Authority only, the applicant to the Competent Authority needs to sign.

(13) On an application to the Ethics Committee only, the applicant to the Ethics Committee needs to sign.